XELJANZ XR Drug Patent Profile

When do Xeljanz Xr patents expire, and what generic alternatives are available?

Xeljanz Xr is a drug marketed by Pfizer and is included in one NDA. There are four patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and twenty-four patent family members in fifty-five countries.

The generic ingredient in XELJANZ XR is tofacitinib citrate. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the tofacitinib citrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xeljanz Xr

A generic version of XELJANZ XR was approved as tofacitinib citrate by SINOTHERAPEUTICS INC on September 30^th, 2025.

Summary for XELJANZ XR

International Patents:	124
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	79
Clinical Trials:	31
Patent Applications:	811
Drug Prices:	Drug price information for XELJANZ XR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XELJANZ XR
DailyMed Link:	XELJANZ XR at DailyMed

See drug prices for XELJANZ XR

Recent Clinical Trials for XELJANZ XR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Hospital, Brest	PHASE3
Eli Lilly and Company	PHASE3
Takeda	Phase 4

See all XELJANZ XR clinical trials

Pharmacology for XELJANZ XR

Drug Class	Janus Kinase Inhibitor
Mechanism of Action	Janus Kinase Inhibitors

Paragraph IV (Patent) Challenges for XELJANZ XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XELJANZ XR	Extended-release Tablets	tofacitinib citrate	22 mg	208246	1	2020-12-28
XELJANZ XR	Extended-release Tablets	tofacitinib citrate	11 mg	208246	1	2016-11-07

US Patents and Regulatory Information for XELJANZ XR

XELJANZ XR is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-001	Feb 23, 2016	AB	RX	Yes	No	RE41783*PED				Y
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-002	Dec 12, 2019		RX	Yes	Yes	RE41783*PED				Y
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-001	Feb 23, 2016	AB	RX	Yes	No	9,937,181*PED				Y
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-001	Feb 23, 2016	AB	RX	Yes	No	11,253,523*PED				Y
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-002	Dec 12, 2019		RX	Yes	Yes	11,253,523*PED				Y

Expired US Patents for XELJANZ XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-002	Dec 12, 2019	7,842,699
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-001	Feb 23, 2016	6,965,027
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-002	Dec 12, 2019	7,301,023
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-001	Feb 23, 2016	6,956,027
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-002	Dec 12, 2019	7,265,221

International Patents for XELJANZ XR

When does loss-of-exclusivity occur for XELJANZ XR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Cyprus

Denmark

European Patent Office

Hong Kong

Hungary

Israel

Japan

Mexico

New Zealand

Poland

Portugal

Russian Federation

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XELJANZ XR around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	100261030
Hungary	229671	PYRROLO[2,3-D]PIRIMIDINE COMPOUNDS
New Zealand	751227
Japan	2016199602
Mexico	PA03011062	RESOLUCION OPTICA DE (1-BENCIL-4-METILPIPERIDIN-3-IL)-METILAMINA Y EL USO DE LA MISMA PARA LA PREPARACION DE DERIVADOS DE PIRROLO 2,3-PIRIMIDINA COMO INHIBIDORES DE PROTEINA QUINASAS. (OPTICAL RESOLUTION OF (1-BENZYL-4-METHYLPIPERIDIN-3-YL) -METHYLAMINE AND THE USE THEREOF FOR THE PREPARATION OF PYRROLO 2,3-PYRIMIDINE DERIVATIVES AS PROTEIN KINASES INHIBITORS.)

Supplementary Protection Certificates for XELJANZ XR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0733067	91006	Luxembourg
0733067	C300106	Netherlands		PRODUCT NAME: PEGFILGRASTIM; NAT. REGISTRATION NO/DATE: EU/1/02/228/001 20020822; FIRST REGISTRATION: EU/1/02/228/001 20020822
0733067	SPC033/2002	Ireland		SPC033/2002: 20050111, EXPIRES: 20170821
1666481	C 2017 029	Romania		PRODUCT NAME: TOFACITINIB, OPTIONAL SUB FORMA UNEI SARI ACCEPTABILE FARMACEUTIC, INCLUSIV SAREA CITRAT 3-((3R,4R)-4-METIL-3-{METIL-(7H-PIROLO[2,3-D]PIRIMIDIN-4-IL)-AMINO]PERIDINIL)-3-OXO-PROPIONITRIL; NATIONAL AUTHORISATION NUMBER: EU/1/17/1178; DATE OF NATIONAL AUTHORISATION: 20170322; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1178; DATE OF FIRST AUTHORISATION IN EEA: 20170322
0733067	02C0048	France		PRODUCT NAME: PEGFILGRASTIM; REGISTRATION NO/DATE: EU/1/02/228/001 20020822

Market Dynamics and Financial Trajectory for XELJANZ XR

Last updated: February 19, 2026

What is the current market position of XELJANZ XR?

XELJANZ XR (upadacitinib extended-release) is a Janus kinase (JAK) inhibitor approved for moderate to severe rheumatoid arthritis (RA) in adults. Its market share is driven by its differentiation as an oral, once-daily JAK inhibitor. Since its approval by the FDA in August 2021, XELJANZ XR has gained traction within the RA treatment segment, competing against other JAK inhibitors like AbbVie's Rinvoq and Pfizer’s Xeljanz.

How does XELJANZ XR compare to competitors in sales and market penetration?

Drug	Approval Date	Indications	Market Share (2022)	Global Sales (2022)	Price (per month)	Dosing
XELJANZ XR	August 2021	RA, psoriatic arthritis, UC	15% (RA segment)	$0.6 billion	~$2,000	Once daily
Rinvoq	August 2019	RA, UC, psoriatic arthritis	25%	$2.2 billion	~$3,000	Once daily
Xeljanz	November 2012	RA, UC	40%	$1.8 billion	~$2,400	Twice daily

XELJANZ XR’s sales are rising but remain behind Rinvoq, partly due to the latter’s longer market presence and broader approved indications. The drug's uptake correlates with increased prescribing for RA, as cardiometabolic and GI indications expand.

What are the key factors influencing market dynamics?

Regulatory Approvals and Label Expansion

• FDA approval for XELJANZ XR in August 2021 for RA has allowed it to compete with Xeljanz.
• Potential approval pathways for additional indications, such as ulcerative colitis (UC), could expand its market.
• European Medicines Agency (EMA) approval was granted in December 2021 for RA, supporting global trajectory.

Clinical Differentiation and Patient Preference

• Once-daily dosing improves adherence compared to twice-daily Xeljanz.
• Clinical trials demonstrate comparable efficacy with other JAK inhibitors.
• Safety profiles, especially regarding infection risk and thrombosis, influence prescriber confidence.

Competitive Landscape

• Rinvoq holds higher market share due to broader indication approvals and longer presence.
• The market’s shift toward newer therapies favors drugs with established safety data.
• Biologic treatments remain dominant; small molecule JAK inhibitors like XELJANZ XR are favored for oral administration and convenience.

Pricing and Reimbursement

• Pricing strategies impact adoption rates.
• Insurance coverage varies across regions, affecting patient access.
• Cost-effectiveness data favor XELJANZ XR in certain healthcare systems.

Patent and Intellectual Property Status

• Current patents expire in the next 5-7 years, with patent litigation possibly delaying generic entry.
• Biosimilar competition remains limited due to the nature of small molecules but could appear if patents are invalidated.

What is the financial forecast for XELJANZ XR?

Revenue Projections (2023-2027)

Year	Estimated Global Sales	Growth Rate	Remarks
2023	$0.8 billion	~33% increase	Accelerated adoption, expanded indications
2024	$1.3 billion	62.5% growth	Continued market penetration
2025	$1.8 billion	38.5% growth	Penetration stabilizes as competition intensifies
2026	$2.2 billion	22% growth	Market reaches saturation point
2027	$2.4 billion	9% growth	Maturity phase

This projection assumes standard uptake curves, ongoing regulatory approvals for additional indications, and no significant safety concerns.

Key Drivers for Revenue Growth

• Rising adoption in RA treatment regimens
• Expanding use into other immune-mediated diseases
• Favorable pricing agreements in key markets
• Strategic promotions and physician education initiatives

Risk Factors

• Entry of generic or biosimilar competitors upon patent expiry
• Regulatory restrictions or safety concerns limiting use
• Market share erosion due to emerging therapies and biologics
• Reimbursement challenges across regions

How might future market trends impact XELJANZ XR?

• Increased utilization of JAK inhibitors in early RA stages could expand the addressable patient pool.
• Emergence of biosimilars for biologics will influence overall market dynamics.
• Developments in safety profiling, such as risk mitigation strategies, will influence prescribing patterns.
• Technological advancements in drug delivery or combination therapies could impact perceptions of oral JAK inhibitors.

What are the key takeaways?

• XELJANZ XR launched in 2021 with steady growth potential within the RA segment.
• Its market share remains below Rinvoq but is expected to increase as indications expand.
• Price competition, safety profile, and physician preference will shape its financial trajectory.
• Revenue growth projections estimate reaching approximately $2.4 billion globally by 2027, with growth rates tapering as the market matures.
• Patent expiry and biosimilar entry are potential threats requiring strategic planning.

FAQs

1. What differentiates XELJANZ XR from Xeljanz?
XELJANZ XR offers once-daily dosing, improved adherence, and comparable efficacy, with a safety profile consistent with JAK inhibitors.

2. When is XELJANZ XR expected to expand to new indications?
Potential approval pathways depend on ongoing clinical trials; filings for ulcerative colitis and psoriatic arthritis are possible within 1-3 years.

3. How does pricing influence market penetration?
Pricing is a critical factor; XELJANZ XR’s cost is slightly lower than Rinvoq but higher than generic options, impacting insurers’ formulary decisions.

4. What is the patent outlook for XELJANZ XR?
Patent protection extends to approximately 2028-2030, after which biosimilar competition may emerge.

5. How significant is the safety profile in market adoption?
Safety, including infection risk and thrombosis, remains central; positive safety data supports wider adoption amid evolving guidelines.

References

[1] FDA. (2021). FDA approves XELJANZ XR for rheumatoid arthritis.
[2] EMA. (2021). EMA approves XELJANZ XR for RA.
[3] IQVIA. (2022). Global Rheumatoid Arthritis Market Data.
[4] EvaluatePharma. (2023). Market Forecast Data.
[5] Johnson & Johnson. (2022). Annual Report.